Management

Adding daratumumab to bortezomib, cyclophosphamide, and dexamethasone led to higher frequencies of hematologic complete response and survival free from major organ deterioration or hematologic progression in patients with newly diagnosed AL. Read More ›

In patients with light chain amyloidosis and cardiac involvement, treatment with D-VCd resulted in higher rates of cardiac response, with possible improvement in fatigue-related variables. Read More ›

Preliminary findings suggest that diflunisal may be a cost-effective alternative for patients with transthyretin amyloid cardiomyopathy who may not be able to afford tafamidis. Read More ›

Subscribe to Amyloidosis News

Stay up to date with Amyloidosis News & updates by subscribing to receive the free AMN e‑Newsletter.

I'd like to receive: